Our team brings together pioneers in NK cells and leaders in cell therapy product development.
Founded by pioneers in NK cell engineering and biology and steered by a leadership team with deep cell therapy experience, Catamaran has assembled the collective expertise to develop transformative cell therapies to treat cancer.
We have a purpose-built team of scientists and drug developers who have the specific know-how and proven track records needed to design, develop and manufacture novel CAR-NK cell therapies. We have come together at Catamaran to discover and develop CAR-NK cell therapies that will change the lives of cancer patients.
Our scientific founders, Branden Moriarity, PhD of the University of Minnesota and Catherine Bollard, MD of the George Washington University Cancer Center, are pioneers in NK cell biology, engineering, manufacturing and clinical application. Both of our founders are proven innovators in cell therapy and bring complementary expertise, with Dr. Moriarity’s discoveries in non-viral cell engineering and Dr. Bollard’s discoveries related to potency-boosting switches for NK cells.
The Catamaran leadership team has deep expertise building cell therapy platforms and rapidly advancing product pipelines. Each member of our team has worked in the emerging cell therapy field with first-hand experience discovering and developing cell therapy products. From NK cell biology and synthetic biology through translation to the clinic and product manufacturing, we bring our unique insights and passion to develop improved cell therapies for patients.